Denali Therapeutics (NASDAQ:DNLI) Trading Down 5.8%

Denali Therapeutics Inc. (NASDAQ:DNLI) was down 5.8% during mid-day trading on Monday . The stock traded as low as $21.81 and last traded at $21.88. Approximately 590,228 shares were traded during trading, a decline of 51% from the average daily volume of 1,198,983 shares. The stock had previously closed at $23.22.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $95.00 target price on shares of Denali Therapeutics in a research note on Wednesday, May 8th. Stifel Nicolaus lowered their price target on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a research report on Wednesday, May 8th. Wedbush lowered their price target on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, May 8th. Finally, UBS Group lowered their target price on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, April 9th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $40.22.

Denali Therapeutics Trading Down 2.0 %

The stock has a market cap of $3.04 billion, a P/E ratio of -22.19 and a beta of 1.39. The business has a 50-day simple moving average of $19.69 and a 200 day simple moving average of $19.27.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.01. During the same quarter last year, the company posted ($0.80) EPS. As a group, equities analysts expect that Denali Therapeutics Inc. will post -2.78 earnings per share for the current year.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, Director Jennifer E. Cook sold 1,458 shares of the business’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $21.73, for a total value of $31,682.34. Following the transaction, the director now directly owns 20,038 shares of the company’s stock, valued at $435,425.74. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Jennifer E. Cook sold 1,458 shares of the firm’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $21.73, for a total value of $31,682.34. Following the completion of the sale, the director now directly owns 20,038 shares in the company, valued at approximately $435,425.74. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $18.29, for a total value of $30,471.14. Following the completion of the sale, the director now directly owns 118,043 shares of the company’s stock, valued at approximately $2,159,006.47. The disclosure for this sale can be found here. Insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CWM LLC grew its holdings in Denali Therapeutics by 216.7% during the fourth quarter. CWM LLC now owns 2,011 shares of the company’s stock worth $43,000 after buying an additional 1,376 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Denali Therapeutics by 879.5% in the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock valued at $48,000 after purchasing an additional 1,847 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Denali Therapeutics by 48.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock valued at $53,000 after purchasing an additional 807 shares in the last quarter. Fisher Asset Management LLC purchased a new position in Denali Therapeutics during the fourth quarter worth about $59,000. Finally, Assetmark Inc. grew its position in Denali Therapeutics by 65.3% in the 4th quarter. Assetmark Inc. now owns 3,550 shares of the company’s stock worth $76,000 after purchasing an additional 1,402 shares in the last quarter. 92.92% of the stock is owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.